Attached files
| file | filename |
|---|---|
| EX-31.2 - EXHIBIT 31.2 - Mirati Therapeutics, Inc. | mrtx-20141231xex312.htm |
| EX-31.1 - EXHIBIT 31.1 - Mirati Therapeutics, Inc. | mrtx-20141231xex311.htm |
| EX-32.1 - EXHIBIT 32.1 - Mirati Therapeutics, Inc. | mrtx-20141231xex321.htm |
| EX-23.2 - EXHIBIT 23.2 - Mirati Therapeutics, Inc. | mrtx-20141231xex232.htm |
| EX-10.22 - EXHIBIT 10.22 - Mirati Therapeutics, Inc. | mrtx-20141231xex1022christ.htm |
| EXCEL - IDEA: XBRL DOCUMENT - Mirati Therapeutics, Inc. | Financial_Report.xls |
| 10-K - 10-K - Mirati Therapeutics, Inc. | mrtx-20141231x10k.htm |
Exhibit 23.1
CONSENT OF ERNST & YOUNG LLP, INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) Registration Statement (Form S-3 No. 333-198678) of Mirati Therapeutics, Inc.,
(2) Registration Statement (Form S-8 No. 333-189965) pertaining to the Amended and Restated Incentive Stock Option Plan, 2013 Equity Incentive Plan, and 2013 Employee Stock Purchase Plan of Mirati Therapeutics Inc., and
(3) Registration Statement (Form S-8 No. 333-196487) pertaining to the 2013 Equity Incentive Plan of Mirati Therapeutics, Inc.;
of our report dated March 11, 2015, with respect to the consolidated financial statements of Mirati Therapeutics, Inc. included in this Annual Report (Form 10-K) of Mirati Therapeutics, Inc. for the year ended December 31, 2014.
/s/ Ernst & Young LLP
San Diego, California
March 11, 2015